Inventor(s): Watkins and Huse

Serial No.: 09/203,768 Filed: December 2, 1998

Page 2

*** , A ...

AMENDMENTS

Please cancel claim 5 without prejudice.

Please amend the claims as follows:

- fragment thereof, comprising the amino acid sequence of SEQ ID NO:2, or having a conservative substitution of an amino acid thereof, and the amino acid sequence of SEQ ID NO:4, or having a conservative substitution of an amino acid thereof, wherein said antibody or functional fragment thereof binds a neoplastic cell or antigen thereof and wherein said antibody or functional fragment thereof having a conservative substitution of an amino acid binds the same neoplastic cell or antigen thereof as said antibody or functional fragment comprising SEQ ID NOS:2 and 4.
- 2. (original) The human monoclonal antibody of claim 1, wherein said functional fragment is selected from the group consisting of Fv, Fab, Fab', or F(ab')₂.
- 3. (original) The human monoclonal antibody or functional fragment of claim 1, further comprising a label.
- 4. (original) The human monoclonal antibody or functional fragment of claim 3, wherein said label comprises a cytotoxic or cytostatic agent.

Claim 5 canceled.

fragment thereof, comprising a heavy chain variable region having the three CDR sequences of the amino acid sequence of SEQ ID NO:2, or having a conservative substitution of an amino acid thereof, and a light chain variable region having the three CDR sequences of the amino acid sequence of SEQ ID NO:4, or having a conservative substitution of an amino acid thereof, wherein said antibody or functional fragment thereof binds a neoplastic cell or antigen thereof and wherein said antibody or functional fragment thereof having a conservative substitution of

Inventor(s): Watkins and Huse

Serial No.: 09/203,768 Filed: December 2, 1998

Page 3

an amino acid binds the same neoplastic cell or antigen thereof as said antibody or functional fragment comprising SEQ ID NOS:2 and 4.

(previously presented) The human monoclonal antibody or functional fragment of claim 1, further comprising a physiologically acceptable compound.

7 48. (previously presented) The human monoclonal antibody of claim 1, wherein said human monoclonal antibody is purified.